Why the study?
Longer survival in patients with cancer has increased vulnerability to drug-related adverse cardiovascular events like cardiomyopathy, particularly with anthracyclines and trastuzumab.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
The paper discusses asymptomatic ventricular dysfunction and HFrEF secondary to classic chemotherapies such as anthracyclines and trastuzumab.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ávila et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: